172733-08-3

Basic information

• Product Name: Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester
• CAS NO: 172733-08-3
• Molecular Formula: C22H22N2O5
• Molecular Weight: 394.427
• Mol File: 172733-08-3.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester(172733-08-3)
• EPA Substance Registry System: Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester(172733-08-3)

Safety Data

• Hazardous Substances Data: 172733-08-3(Hazardous Substances Data)

Upstream product

• 79-37-8 oxalyl dichloride 
• 172733-07-2 2-[[2-Ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester 
• 172733-06-1 1-benzyl-2-ethyl-1H-indol-4-ol 
• 948553-63-7 (1-Benzyl-3-chlorooxalyl-2-ethyl-1H-indol-4-yloxy)-acetic acid methyl ester 
• 164082-80-8 1-benzyl-2-ethyl-4-methoxy-1H-indole 

Downstream Products

• 172732-68-2 ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid 
• 172733-42-5 sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate 
• 331440-80-3 2-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl] oxy]-N-(hydroxy)acetamide 

Relevant articles and documents

PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM 3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE

A lyophilized pharmaceutical composition is described which contains Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate, a Solubilizer, and a Stabilizer. Such compositions are storage stable and readily dissolve in aqueous medium to give injectable solution for treatment of sepsis, etc.

Novel sPLA2 inhibitors

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

Combination therapy for the treatment of inflammatory and respiratory diseases

A pharmaceutical composition for the treatment of Inflammatory Disease or Respiratory Disease in mammals, which comprises, as active ingredients, a neutrophil elastase inhibitor and an sPLA2 inhibitor.